2020
Emerging Meningioma Therapies I: Precision Medicine, Targeted Therapies, and Mutation-Specific Approaches
Roque A, Omuro A. Emerging Meningioma Therapies I: Precision Medicine, Targeted Therapies, and Mutation-Specific Approaches. 2020, 217-226. DOI: 10.1007/978-3-030-59558-6_14.Peer-Reviewed Original ResearchLarge-scale genetic analysisEpigenetic informationMutation-specific approachesGenetic analysisMolecular characterizationMeningioma tumorigenesisMutational loadMethylation statusAbove mutationsMutationsMolecular landscapeMolecular changesNF2 geneGenesCurrent understandingAggressive phenotypeNF2 mutationsNew avenuesPotential biomarkersKLF4AKT1TumorigenesisPhenotypeTherapeutic interventionsTRAF7
2005
EGFR tyrosine kinase domain mutations in human gliomas
Marie Y, Carpentier A, Omuro A, Sanson M, Thillet J, Hoang-Xuan K, Delattre J. EGFR tyrosine kinase domain mutations in human gliomas. Neurology 2005, 64: 1444-1445. PMID: 15851741, DOI: 10.1212/01.wnl.0000158654.07080.b0.Peer-Reviewed Original ResearchConceptsLung cancerEGFR tyrosine kinase domain mutationsEpidermal growth factor receptor tyrosine kinase inhibitorsGrowth factor receptor tyrosine kinase inhibitorsTyrosine kinase domain mutationsReceptor tyrosine kinase inhibitorsKinase domain mutationsTyrosine kinase inhibitorsLow-grade gliomasEGFR tyrosine kinase domainResistance of glioblastomaAnaplastic oligodendrogliomaHuman gliomasGliomasTyrosine kinase domainExon 19Kinase inhibitorsDomain mutationsGefitinibCancerGlioblastomaSuch mutationsMutationsPatientsEGFR